TP53 and liver cancer: Under a strict threshold (see Methods), we identified 893 specific clonal non-silent somatic mutated genes (ranged from 5 to 234 per patient; median, 15) (Figure 1A), including the known frequent liver cancer driver genes TP53 (Chasov et al., 2020) (occurred in 96 patients, 27.3%), CTNNB1 (76 patients, 21.6%), TTN (72 patients, 20.1%), MUC16 (46 patients, 13.1%) and APOB (28 patients, 8.0%) (Tate et al., 2019) (Figure 1B).